ERBB2 and breast carcinoma: In our series, total visceral fat is the most important factor related to worse outcome, and it might suggest that in HER2-positive breast cancer disease total abdominal fat tissue could have a key role to predict response to newly anti-HER2 treatments, as already shown in preclinical models39.